Program

The Virtual Global Forum program will include presentation and panel discussions focused on progress and key issues in TB vaccine R&D against the backdrop of the COVID-19 pandemic.

Click here to view the program-at-a-glance.

Program and speaker details will be added to this page as they are confirmed.

We recognize that the timing of sessions will not be convenient for all who wish to participate. Sessions will be made available on-demand for registered participants following the Global Forum so that you can view sessions that you were unable to join at the scheduled time.

All times are Eastern Daylight Time.

Tuesday 20 April 2021

9:00 – 10:00

Opening Session

10:15 - 11:45

SCIENTIFIC SESSION: NOVEL INSIGHTS AND APPROACHES TO TB VACCINE R&D

This session will focus on new insights and approaches to TB vaccine R&D, including novel insights into the granuloma and protective immunity, as well as a novel platform for TB vaccine.

The presentations in this session will be prerecorded. Speakers will be online during the presentation time to respond to questions and engage in the discussion.

SPEAKERS

  • Micheal Gerner, University of Washington (USA)
  • Andrea Cooper, University of Leicester (UK)
  • Lenette Lu, UT Southwestern Medical Center (USA)
  • Hannah Gideon, University of Pittsburgh School of Medicine (USA)

Other speakers to be announced

12:00 – 13:00

CONCURRENT SESSIONS

Wednesday 21 April 2021

9:00 - 10:30

Scientific Session: Clinical Development of New TB Vaccines

This session will provide an overview of issues in clinical research and brief updates on TB vaccine candidates in late-stage development.

The presentations in this session will be prerecorded. Speakers will be online during the presentation time to respond to questions and engage in the discussion.

SPEAKERS

  • Ann M. Ginsberg, Bill & Melinda Gates Foundation (USA)
  • Alexander Schmidt, Gates Medical Research Institute (USA)
  • C. Fordham von Reyn, Dartmouth Geisel School of Medicine (USA)
  • Alvaro Borges, Statens Serum Institut (Denmark)
  • Sajjad Desai, Serum Institute of India (India)

Other speakers to be announced

10:45 - 11:45

Panel Discussion: Policy and Access Issues for TB Vaccines

Rapid uptake of future TB vaccines will be needed to deliver health and economic impact in affected countries, but historical experience indicates however that uptake of new vaccines tends to be significantly delayed precisely in countries where the need is the greatest. Building on previous introduction and implementation experiences, this panel will discuss how TB vaccine stakeholders can work together, across sectors and along the full research continuum, to plan for accelerated global access to new TB vaccines.

Panelists to be announced

12:00 - 13:00

Concurrent Sessions

Thursday 22 April 2021

9:00 - 10:30

Scientific Session: BCG 100 Years Later

This year marks 100 years since BCG was first used, but there is still much to be learned about this century-old vaccine. This session will provide an overview of recent learnings about BCG, innate immunity, BCG revaccination, clinical research underway to test BCG for COVID and other respiratory infections, and issues of market dynamics and supply.

The presentations in this session will be prerecorded. Speakers will be online during the presentation time to respond to questions and engage in the discussion.

SPEAKERS

  • Helen McShane, University of Oxford (UK)
  • Simone Joosten, Leiden University Medical Center (Netherlands)
  • Gavin Churchyard, Aurum Institute (South Africa)
  • Richard White, London School of Hygiene and Tropical Medicine (UK)

Other speakers to be announced

10:45 - 11:45

Panel discussion: Leveraging COVID-19 to advance to vaccine R&D

COVID-19 vaccine development is happening at an unprecedented speed, drawing on extraordinary resources, including R&D capacity. Some of the results of this global effort will result in licensure of COVID-19 vaccines based on established vaccine technologies, validation of novel vaccine platforms and technologies, accelerated regulatory pathways, and systems for anticipated implementation. This panel session will discuss how these advances could leveraged for TB and other infectious diseases.

Panelists to be announced

12:00 - 13:00

Panel discussion: Closing the Financing Gap for TB Vaccine R&D

The funding gap continues to be one of the biggest challenges for TB vaccine development. TB R&D funding in 2019 reached $900 million, less than half of the US$2 billion/year target agreed by member states at the UN High level meeting on TB in 2018. Enhanced progress in the discovery, translational and especially advanced clinical development of new TB vaccines requires considerably more funding to reach fruition. Panellists in this session will assess the main barriers to closing the funding gap on TB vaccine R&D and discuss strategies and solutions to address these barriers and build support for TB vaccines R&D across the research continuum.

Panelists to be announced

13:00 - 13:30

Closing session

Sign up for information and updates about the Global Forum